ArticlePediatric gastroenterology, hepatology & nutrition2026
Evaluation of the Impact of the COVID-19 Pandemic on the Clinical Presentation of Pediatric Celiac Disease.
Article in Pediatric gastroenterology, hepatology & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the impact of the coronavirus disease (COVID-19) pandemic on the clinical presentation, serological load, and duodenal histopathological damage in pediatric celiac disease (CD) patients compared to the pre-pandemic period. Methods: This retrospective cohort study included 114 pediatric patients with biopsy-confirmed CD diagnosed between June 2017 and November 2021. The study population was divided into a Pandemic Group (n=57) and a Pre-Pandemic Control Group (n=57). To ensure histopathological comparability, patients diagnosed without biopsy due to high antibody titers were excluded. Demographic data, clinical symptoms, anti-tissue transglutaminase antibody (anti-tTG) IgA/IgG titers, and Modified Marsh scores were analyzed. Results: The median age at diagnosis was significantly higher in the Pandemic Group compared to the Pre-Pandemic Group ( Conclusion: The COVID-19 pandemic resulted in a significant delay in diagnosis age and an increased serological load in pediatric CD cases. However, this increased load did not correspond to a significant worsening in duodenal mucosal damage. These results underscore the critical importance of maintaining diagnostic pathways for chronic conditions during health crises.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.